INDIGO Biosciences, Inc. was founded in 2005 in State College, PA. It remains a privately held biosciences company offering products and services focused on nuclear receptors, which comprise a major class of therapeutic drug targets.
The Company's two founders, Dr. Jack Vanden Heuvel and Dr. Blake Peterson, leveraged their collective expertise's in nuclear receptor biology, toxicology, medicinal chemistry and molecular biology to establish the core platform technology of The Company.
INDIGO Biosciences' original focus was that of a traditional contract research organization, namely, to provide custom services for the screening of small molecule compounds against functional human and non-human nuclear receptors. Over the years, The Company has demonstrated success in providing quality screening services to clients within the pharmaceutical, biotechnology, food, agriculture and nutriceutical industries, government research agencies, as well as to academic researchers.
INDIGO Biosciences continues to provide high-quality, confidential screening services for drug discovery and active ingredient determination.
However, in 2008 The Company's mission changed dramatically. Instead of being strictly a service provider, INDIGO Biosciences is now dedicated to establishing itself as the premier provider of cell-based nuclear receptor reporter assay products.
The technology that enabled this transformation was The Company's development of a unique and superior processing method to cryo-preserve its nuclear receptor reporter cells. This proprietary process, called CryoMite™, provides long-term cryo-preservation of cells for shipping and storage, providing users the convenience of readily available robust cell-based reporter assays for on-demand use.
Mr. H. Dean Bunnell joined The Company in 2007 as President & Chief Executive Officer. Mr. Bunnell has over 30 years of management and business development experience in high tech companies. Work history includes founding and managing MAXTECH, Inc. in State College PA (a.k.a. Vertex Electronic Products), as well as holding management positions at Mitsubishi, NEC, Aercom Industries, and CTT. Mr. Bunnell may be contacted via e-mail at
Dr. Jack Vanden Heuvel is one of The Company's original founders, and currently serves as Chief Scientific Officer. Dr. Vanden Heuvel is a recognized expert in the field of nuclear receptor biology and toxicology. Dr. Vanden Heuvel may be contacted via e-mail at
Dr. Bruce A. Sherf joined The Company in 2008 as the Chief Technology Officer. Dr. Sherf, who has worked in the biotechnology industry since 1994, has particular expertise in cell-based reporter assay design and optimization, product development, and high-throughput screening applications for drug discovery. As CTO, he oversees INDIGO Biosciences' product development, manufacturing, and technology transfer initiatives, as well as directing all Contract Services related activities. Dr. Sherf may be contacted via e-mail at
Mr. Mark J. Capriani joined The Company in 2010 as Vice President, Sales and Marketing. Mr. Capriani has worked in the biopharmaceutical industry since 1992, and has experience in all aspects of sales, marketing, business development and building distribution channels. Mr. Capriani may be contacted via e-mail at